<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOPREEZA- estradiol and norethindrone acetate tablet, film coated </strong><br>Amneal Pharmaceuticals of New York, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use Lopreeza safely and effectively. See full prescribing information for Lopreeza.</span><br><br><span class="Bold">Lopreeza™ (estradiol/norethindrone acetate) tablets, for oral use </span><br><span class="Bold">Initial U.S. Approval: 1998</span>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Italics"><span class="Bold">See full prescribing information for complete boxed warning</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy</span></span></h1>
<ul class="Disc">
<li><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">(5.1,</a> <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">5.3)</a> </span></li>
<li><span class="Bold">The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">(5.1)</a> </span></li>
<li><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">(5.2)</a> </span></li>
<li><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">(5.3)</a> </span></li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span> </p>
<ul class="Disc">
<li><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who use unopposed estrogens <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">(5.2)</a> </span></li>
<li><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">(5.2,</a> <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">5.3)</a> </span></li>
<li><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">(5.1)</a> </span></li>
<li>
<span class="Bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">(5.3)</a> </span> </li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Contraindications <a href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">(4)</a>                                                                                10/2013 </p>
<p class="Highlighta">Warnings and Precautions, Hereditary Angioedema <a href="#LINK_615c3caa-0601-41ef-8e03-155bae9a0191">(5.15)</a>                     10/2013 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Italics"><span class="Bold">See full prescribing information for complete boxed warning</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy</span></span></h1>
<ul class="Disc">
<li><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">(5.1,</a> <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">5.3)</a> </span></li>
<li><span class="Bold">The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">(5.1)</a> </span></li>
<li><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">(5.2)</a> </span></li>
<li><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">(5.3)</a> </span></li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span> </p>
<ul class="Disc">
<li><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who use unopposed estrogens <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">(5.2)</a> </span></li>
<li><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">(5.2,</a> <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">5.3)</a> </span></li>
<li><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">(5.1)</a> </span></li>
<li>
<span class="Bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">(5.3)</a> </span> </li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Lopreeza is an estrogen and progestin combination indicated in a woman with a uterus for: </p>
<p class="Highlighta">Lopreeza 1 mg/0.5 mg and 0.5 mg/0.1 mg are indicated in a woman with a uterus for: </p>
<ul class="Disc">
<li>Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> <a href="#LINK_f4288774-59ba-4255-b94d-8d06e72a531e">(1.1)</a> </li>
<li>Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> <a href="#LINK_d3fcbae6-01de-469c-8945-1cfa05ecdf7b">(1.3)</a> </li>
</ul>
<p class="Highlighta">Lopreeza 1 mg/0.5 mg is also indicated in a woman with a uterus for: </p>
<ul class="Disc"><li>Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> <a href="#LINK_d5b8decf-f74a-4ee1-9be7-b2f63965245e">(1.2)</a> </li></ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc"><li>One tablet to be taken once daily <a href="#LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">(2)</a> </li></ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>Lopreeza (estradiol/norethindrone acetate) 1 mg/0.5 mg tablet <a href="#LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">(3)</a> </li>
<li>Lopreeza (estradiol/norethindrone acetate) 0.5 mg/0.1 mg tablet <a href="#LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">(3)</a> </li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<ul class="Disc">
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <a href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">(4)</a> </li>
<li>Known, suspected, or history of breast cancer <a href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">(4,</a> <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">5.2)</a> </li>
</ul>
<ul class="Disc"><li>Known or suspected estrogen-dependent neoplasia <a href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">(4,</a> <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">5.2)</a> </li></ul>
<ul class="Disc"><li>Active DVT, PE, or history of these conditions <a href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">(4,</a> <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">5.1)</a> </li></ul>
<ul class="Disc"><li>Active arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and MI), or a history of these conditions <a href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">(4,</a> <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">5.1)</a> </li></ul>
<ul class="Disc"><li>Known <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Lopreeza <a href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">(4)</a> </li></ul>
<ul class="Disc">
<li>Known liver impairment or disease <a href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">(4,</a> <a href="#LINK_a2a395bd-a492-47e5-8e82-345070e1478f">5.10)</a> </li>
<li>Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders <a href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">(4)</a> </li>
<li>Known or suspected pregnancy <a href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">(4,</a> <a href="#LINK_c7ddff79-330d-427b-b47b-400ef0464579">8.1)</a> </li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Estrogens increase the risk of gall bladder disease <a href="#LINK_0de60a6a-b583-4c50-ade9-0d6051dd4c06">(5.4)</a> </li>
<li>Discontinue estrogen if severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> or <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> occurs <a href="#LINK_6cd7176c-d17e-403d-9e04-8707d1a2d2e9">(5.5,</a> <a href="#LINK_3d26abc2-417e-4ecb-a9c9-c25fc51793e7">5.6,</a> <a href="#LINK_bf4bef54-ce59-4e36-a1f3-cc18c95fd817">5.9,</a> <a href="#LINK_a2a395bd-a492-47e5-8e82-345070e1478f">5.10)</a> </li>
<li>Monitor thyroid function in women on thyroid replacement therapy <a href="#LINK_4b26f764-d92d-457a-a4a7-78a83ffb0aba">(5.11,</a> <a href="#LINK_152548a0-9352-4ec2-bed0-0da1264462c2">5.18)</a> </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥ 5 percent) are <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the extremity, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, post-menopausal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">uterine fibroid</span> <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cyst</span>, endometrial thickening, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="4080452" conceptname="Anogenital candidiasis">moniliasis genital</span>, and <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>. <a href="#LINK_678d76ea-b8d4-4361-8915-76cb0eb365f0">(6.1)</a>  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-888-824-4336 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism <a href="#LINK_f4f5ea9a-d110-46fd-970e-12c745d74fa0">(7.1)</a> </li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Nursing Mothers: Estrogen administration to nursing women has been shown to decrease the quantity and quality of breast milk <a href="#LINK_0fcc4622-7beb-4aeb-bd07-c09345848be3">(8.3)</a> </li>
<li>Geriatric Use: An increase risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women over 65 years of age was reported in the Women’s Health Initiative Memory ancillary studies of the Women’s Health Initiative <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">(5.3,</a> <a href="#LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">8.5)</a>  </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.2" class="toc"><span class="Bold">1.2       Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></span></a></h2>
<h2><a href="#section-1.3" class="toc"><span class="Bold">1.3                   Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1  </span><span class="Bold">Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2                    </span><span class="Bold">Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3       Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1     <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2     Malignant Neoplasms</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3       Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4       <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5       <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6       Vision Abnormalities</span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7       Addition of a Progestin When a Woman Has Not Had a Hysterectomy</span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.8       Elevated Blood Pressure</span></a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold">5.9       Hypertriglyceridemia    </span></a></h2>
<h2><a href="#section-5.10" class="toc"><span class="Bold">5.10     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></span></a></h2>
<h2><a href="#section-5.11" class="toc"><span class="Bold">5.11 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span>     </span></a></h2>
<h2><a href="#section-5.12" class="toc"><span class="Bold">5.12     <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></span></a></h2>
<h2><a href="#section-5.13" class="toc"><span class="Bold">5.13     <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></span></a></h2>
<h2><a href="#section-5.14" class="toc"><span class="Bold">5.14     Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span></span></a></h2>
<h2><a href="#section-5.15" class="toc"><span class="Bold">5.15     <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span></span></a></h2>
<h2><a href="#section-5.16" class="toc"><span class="Bold">5.16     Exacerbation of Other Conditions</span></a></h2>
<h2><a href="#section-5.17" class="toc"><span class="Bold">5.17     Laboratory Tests</span></a></h2>
<h2><a href="#section-5.18" class="toc"><span class="Bold">5.18     Drug-Laboratory Test Interactions   </span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1        Clinical Trials Experience</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6</span>.<span class="Bold">2       Postmarketing Experience</span></a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1       Metabolic Interactions</span></a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.6     <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold">8.7     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">14.1     Effects on Vasomotor Symptoms</span></a></h2>
<h2><a href="#section-13.2" class="toc"><span class="Bold">14.2     Effects on the Endometrium</span></a></h2>
<h2><a href="#section-13.3" class="toc"><span class="Bold">14.3     Effects on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span> or Spotting</span></a></h2>
<h2><a href="#section-13.4" class="toc"><span class="Bold">14.4     Effects on Bone Mineral Density</span></a></h2>
<h2><a href="#section-13.5" class="toc"><span class="Bold">14.5     Women’s Health Initiative Studies</span></a></h2>
<h2><a href="#section-13.6" class="toc"><span class="Bold">14.6 </span><span class="Bold">Women’s Health Initiative Memory Study</span></a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc"><span class="Bold">16.1     How Supplied</span></a></h2>
<h2><a href="#section-15.2" class="toc"><span class="Bold">16.2     Storage and Handling</span></a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc"><span class="Bold">17.1     Abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></span></a></h2>
<h2><a href="#section-16.2" class="toc"><span class="Bold">17.2     Possible Serious Adverse Reactions with Estrogen Plus Progestin Therapy</span></a></h2>
<h2><a href="#section-16.3" class="toc"><span class="Bold">17.3     Possible Less Serious but Common Adverse Reactions with Estrogen Plus Progestin Therapy</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="LINK_bb7ceb11-60f8-401d-96f1-e2c3a6687b98"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></h1>
<p class="First"><span class="Underline"><span class="Bold">Estrogen Plus Progestin Therapy</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></p>
<p><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics">[see <span class="Italics"><a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">Warnings and Precautions (5.1</a></span><span class="Italics"><a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">,</a> ​</span></span><span class="Italics"><span class="Bold"><span class="Italics"><a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">5.3</a></span></span><span class="Bold"><span class="Italics"><a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">)</a></span></span></span></span><span class="Bold"><span class="Italics">, and <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5,</a> <a href="#LINK_208f53fa-35e8-4739-a446-489cbf46d4dd">14.6)</a>]</span></span><span class="Bold">.</span></p>
<p><span class="Bold">The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo <span class="Italics">[see <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">Warnings and Precautions (5.1),</a> and <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]</span>.</span></p>
<p><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics">[see <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">Warnings and Precautions (5.3),</a> <a href="#LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">Use in Specific Populations (8.5),</a> and <a href="#LINK_208f53fa-35e8-4739-a446-489cbf46d4dd">Clinical Studies (14.6)</a>]</span><span class="Italics">.</span></span></p>
<p><span class="Bold">Breast Cancer</span></p>
<p><span class="Bold"> </span></p>
<p><span class="Bold">The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer <span class="Italics">[see <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">Warnings and Precautions (5.2),</a> and <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]</span>.</span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins.</span></p>
<p><span class="Bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</span></p>
<p><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span></p>
<p><span class="Bold">Endometrial Cancer</span></p>
<p><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">Warnings and Precautions (5.2)</a>]</span>.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></p>
<p><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics">[see <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">Warnings and Precautions (5.1,</a> <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">5.3)</a>, and <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5,</a> <a href="#LINK_208f53fa-35e8-4739-a446-489cbf46d4dd">14.6)</a>]</span>.</span></p>
<p><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo <span class="Italics">[see <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">Warnings and Precautions (5.1)</a>, and <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]</span>.</span></p>
<p><span class="Bold">The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics">[see <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">Warnings and Precautions (5.3)</a>, <a href="#LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">Use in Specific Populations (8.5)</a>, and <a href="#LINK_208f53fa-35e8-4739-a446-489cbf46d4dd">Clinical Studies (14.6)</a>]</span>.</span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.</span></p>
<p><span class="Bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f4288774-59ba-4255-b94d-8d06e72a531e"></a><a name="section-1.1"></a><p></p>
<h2>1.1       Treatment of Moderate to Severe Vasomotor Symptoms due
to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d5b8decf-f74a-4ee1-9be7-b2f63965245e"></a><a name="section-1.2"></a><p></p>
<h2><span class="Bold">1.2       Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></span></h2>
<p class="First"><span class="Bold">Limitation of Use</span></p>
<p>When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal  <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, topical vaginal products should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d3fcbae6-01de-469c-8945-1cfa05ecdf7b"></a><a name="section-1.3"></a><p></p>
<h2><span class="Bold">1.3                   Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></span></h2>
<p class="First"><span class="Bold">Limitation of Use</span></p>
<p>When prescribing solely for the prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, therapy should only be considered for women at significant risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and non-estrogen medication should be  carefully considered. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.  Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2f15af65-4057-4e18-bca5-cab4de0f633d"></a><a name="section-2.1"></a><p></p>
<h2>
<span class="Bold">2.1  </span><span class="Bold">Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></span>
</h2>
<p class="First">Lopreeza therapy consists of a single tablet to be taken once daily for the treatment of moderate to severe vasomotor symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.  </p>
<ul class="Disc">
<li>Lopreeza 1 mg/0.5 mg </li>
<li>Lopreeza 0.5 mg/0.1 mg</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1684fc9c-23fa-4c76-9903-a31c90fc9868"></a><a name="section-2.2"></a><p></p>
<h2>
<span class="Bold">2.2                    </span><span class="Bold">Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></span>
</h2>
<p class="First"><span class="Bold"> </span></p>
<p>Lopreeza therapy consists of a single tablet to be taken once daily for the treatment of moderate to severe symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.   </p>
<ul class="Disc"><li>Lopreeza 1 mg/0.5 mg</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a584f93d-baff-4433-9bd0-b2ac049fd1ed"></a><a name="section-2.3"></a><p></p>
<h2><span class="Bold">2.3       Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></span></h2>
<p class="First">Lopreeza therapy consists of a single tablet to be taken once daily for the prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>.    </p>
<ul class="Disc">
<li>Lopreeza 1 mg/0.5 mg </li>
<li>Lopreeza 0.5 mg/0.1 mg</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Lopreeza tablets are available in two strengths: </p>
<ul class="Disc"><li>Each tablet of Lopreeza 1 mg/ 0.5 mg contains 1 mg of estradiol and 0.5 mg of norethindrone acetate.The tablets are white, round, bi-convex, film-coated tablets engraved with NOVO 288 on one side and the APIS bull on the other. </li></ul>
<ul class="Disc"><li>Each tablet of Lopreeza 0.5 mg/ 0.1 mg contains 0.5 mg of estradiol and 0.1 mg of norethindrone acetate.The tablets are white, round, bi-convex, film-coated tablets engraved with NOVO 291 on one side and the APIS bull on the other.</li></ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Lopreeza is contraindicated in women with any of the following conditions:   </p>
<ul class="Disc">
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>Known, suspected, or history of breast cancer</li>
<li>Known, past or suspected estrogen-dependent neoplasia</li>
<li>Active DVT, PE, or history of these conditions</li>
<li>Active arterial thromboembolic disease (for example <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and MI), or a history of these conditions</li>
<li>Known <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Lopreeza</li>
<li>Known liver impairment or disease</li>
<li>Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders</li>
<li>Known or suspected pregnancy<span class="Bold"><br><br></span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_4e1684e1-bdaa-4046-ac6f-e2816f5fb48e"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1     <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></span></h2>
<p class="First">An increased risk of PE, DVT, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and MI has been reported with estrogen plus progestin therapy. An increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT has been reported with estrogen-alone therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (for example, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (VTE) (for example, personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></span></p>
<p>In the WHI estrogen plus progestin substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years) <span class="Italics">[see <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]</span>. The increase in risk was demonstrated after the first year and persisted.<span class="Sup">1</span> Should a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.</p>
<p>In the WHI estrogen-alone substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 1 and persisted <span class="Italics">[see <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]</span>. <span class="Italics"> </span>Should a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur or be suspected, estrogen-alone therapy should be discontinued immediately.</p>
<p>Subgroup analyses of women 50 to 59 years of age suggest no increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).<span class="Sup">1</span></p>
<p><br></p>
<p><span class="Italics">Coronary Heart Disease</span></p>
<p>In the WHI estrogen plus progestin substudy, there was a statistically non-significant increase risk of coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) reported in women receiving  daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years). <span class="Sup">1</span>An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 <span class="Italics">[see <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]</span>.</p>
<p>In the WHI estrogen-alone substudy, no overall effect on CHD events was reported in women receiving estrogen-alone compared to placebo <span class="Sup">2</span><span class="Italics">[see <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>].</span></p>
<p>Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (8 versus 16 per 10,000 women-years).<span class="Sup">1</span>  </p>
<p>In postmenopausal women with documented heart disease (n=2,763), average 66.7 years of age, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), treatment with daily CE (0.625 mg plus MPA (2.5 mg) demonstrated no cardiovascular benefit.  During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD.  There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand, three hundred and twenty‑one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span></span></p>
<p>In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE (DVT and PE), was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted <span class="Sup">3</span><span class="Italics">[see <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]. </span>Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.</p>
<p>In the WHI estrogen-alone substudy, the risk of VTE was increased for women receiving daily CE </p>
<p>(0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years <span class="Sup">4</span><span class="Italics">[see <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]. </span>Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately.</p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2     Malignant Neoplasms</span></h2>
<p class="First"><span class="Italics">Breast Cancer    </span></p>
<p>The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg). After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo <span class="Italics">[see <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]</span>. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years, for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups <span class="Sup">5</span><span class="Italics">[see <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]</span>.</p>
<p>The most important randomized clinical trial providing information about breast cancer in estrogen-alone users is the WHI substudy of daily CE (0.625 mg)-alone. In the WHI estrogen-alone substudy, after an average follow‑up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer <span class="Italics">[relative risk (RR) 0.80 </span><span class="Sup">6</span><span class="Italics">[see <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]</span>.</p>
<p>Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. However, these studies have not found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.</p>
<p>The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation.</p>
<p>In a one-year trial among 1,176 women who received either unopposed 1 mg estradiol or a combination of 1 mg estradiol plus one of three different doses of NETA (0.1, 0.25, 0.5 mg), seven new cases of breast cancer were diagnosed, two of which occurred among the group of 295 women treated with Lopreeza 1.0 mg/0.5 mg and two of which occurred among the group of 294 women treated with 1 mg estradiol/0.1 mg NETA.</p>
<p>All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</p>
<p><span class="Italics">Endometrial Cancer</span></p>
<p><span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> (a possible precursor of endometrial cancer) has been reported to occur at a rate of approximately 1 percent or less with Lopreeza. </p>
<p>An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in nonusers, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears to be associated with prolonged use, with increased risks of 15- to 24‑fold for 5 to 10 years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.</p>
<p>Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy in postmenopausal women has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer.</p>
<p><span class="Italics">Ovarian Cancer</span></p>
<p>The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent CI, 0.77-3.24]. The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years. <span class="Sup">7</span> In some epidemiologic studies, the use of estrogen plus progestin and estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer. However, the duration of exposure associated with increased risk is not consistent across all epidemiologic studies, and some report no association. </p>
<p><span class="Bold"> </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3       Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></h2>
<p class="First">In the WHIMS estrogen plus progestin ancillary study of WHI, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. </p>
<p>After an average follow-up of 4 years, 40 women in the CE plus MPA and 21 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for the CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years <span class="Sup">8</span> <span class="Italics">[see <a href="#LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">Use in Specific Populations (8.5),</a> and <a href="#LINK_208f53fa-35e8-4739-a446-489cbf46d4dd">Clinical Studies (14.6)</a>].</span></p>
<p>In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years <span class="Sup">8</span><span class="Italics">[see <a href="#LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">Use in Specific Populations (8.5)</a>, and <a href="#LINK_208f53fa-35e8-4739-a446-489cbf46d4dd">Clinical Studies (14.6)</a>].</span></p>
<p>When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 percent CI, 1.19-2.60). Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Sup">8</span><span class="Italics">[see <a href="#LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">Use in Specific Populations (8.5)</a>, and <a href="#LINK_208f53fa-35e8-4739-a446-489cbf46d4dd">Clinical Studies (14.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0de60a6a-b583-4c50-ade9-0d6051dd4c06"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4       <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></span></h2>
<p class="First">A 2- to 4 fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogens has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6cd7176c-d17e-403d-9e04-8707d1a2d2e9"></a><a name="section-5.5"></a><p></p>
<h2><span class="Bold">5.5       <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></span></h2>
<p class="First">Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in patients with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>.  If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3d26abc2-417e-4ecb-a9c9-c25fc51793e7"></a><a name="section-5.6"></a><p></p>
<h2><span class="Bold">5.6       Vision Abnormalities</span></h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in patients receiving estrogens. Discontinue medication pending examination if there is a sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.  If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, estrogens should be permanently discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_16d0e602-c274-4d68-b561-5a24dd19f677"></a><a name="section-5.7"></a><p></p>
<h2><span class="Bold">5.7       Addition of a Progestin When a Woman Has Not Had a Hysterectomy</span></h2>
<p class="First">Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would be induced by estrogen treatment alone.  <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a precursor to endometrial cancer.</p>
<p>There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens.  These include an increased risk of breast cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_916ed190-8e7d-4606-afa3-485ea06e49e6"></a><a name="section-5.8"></a><p></p>
<h2><span class="Bold">5.8       Elevated Blood Pressure</span></h2>
<p class="First">In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens.  In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen.    </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bf4bef54-ce59-4e36-a1f3-cc18c95fd817"></a><a name="section-5.9"></a><p></p>
<h2><span class="Bold">5.9       Hypertriglyceridemia    </span></h2>
<p class="First">In women with pre-existing <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Consider discontinuation of treatment if <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a2a395bd-a492-47e5-8e82-345070e1478f"></a><a name="section-5.10"></a><p></p>
<h2><span class="Bold">5.10     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></span></h2>
<p class="First">Estrogens may be poorly metabolized in women with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>.  For women with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, medication should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4b26f764-d92d-457a-a4a7-78a83ffb0aba"></a><a name="section-5.11"></a><p></p>
<h2><span class="Bold">5.11 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span>     </span></h2>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) levels.  Women with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> and T<span class="Sub">3</span> serum concentrations in the normal range.  Women dependent on thyroid hormone replacement therapy who are also receiving estrogen may require increased doses of their thyroid replacement therapy.  These women should have their thyroid function monitored to maintain their free thyroid hormone levels in an acceptable range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_266741ad-c43f-460b-be76-7b61bfac5ab5"></a><a name="section-5.12"></a><p></p>
<h2><span class="Bold">5.12     <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></span></h2>
<p class="First">Estrogens plus progestins may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. Women with conditions that might be influenced by this factor, such as a cardiac or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, warrant careful observation when estrogens plus progestins are prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a20fe310-4c7a-4b79-bf4e-5ffe905fdf33"></a><a name="section-5.13"></a><p></p>
<h2><span class="Bold">5.13     <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></span></h2>
<p class="First">Estrogen therapy should be used with caution in women with <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span> as estrogen-induced <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> may occur. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_986254f8-fb9a-4742-ae2a-6ed2c678584a"></a><a name="section-5.14"></a><p></p>
<h2><span class="Bold">5.14     Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span></span></h2>
<p class="First">A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy.  For women known to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> post-hysterectomy, the addition of progestin should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_615c3caa-0601-41ef-8e03-155bae9a0191"></a><a name="section-5.15"></a><p></p>
<h2><span class="Bold">5.15     <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span></span></h2>
<p class="First">Exogenous estrogens may exacerbate symptoms of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in women with <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">hereditary angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ada5898b-e4b2-416b-8821-1410fb09076e"></a><a name="section-5.16"></a><p></p>
<h2><span class="Bold">5.16     Exacerbation of Other Conditions</span></h2>
<p class="First">Estrogen therapy may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6914ae44-75fc-48d1-807c-1b2d53aea2bf"></a><a name="section-5.17"></a><p></p>
<h2><span class="Bold">5.17     Laboratory Tests</span></h2>
<p class="First">Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_152548a0-9352-4ec2-bed0-0da1264462c2"></a><a name="section-5.18"></a><p></p>
<h2><span class="Bold">5.18     Drug-Laboratory Test Interactions   </span></h2>
<p class="First">Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity, increased levels of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and activity.</p>
<p>Increased TBG levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T<span class="Sub">4 </span>levels (by column or by radioimmunoassay), or T<span class="Sub">3 </span>levels by radioimmunoassay. T<span class="Sub">3 </span>resin uptake is decreased, reflecting the elevated TBG. Free T<span class="Sub">4 </span>and freeT<span class="Sub">3 </span>concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone.</p>
<p>Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/rennin substrate, alpha-1 antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>).</p>
<p><br></p>
<p>Increased plasma high-density lipoprotein (HDL) and HDL<span class="Sub">2</span> <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> subfraction concentration, reduced </p>
<p>low-density lipoprotein (LDL) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, increased triglyceride levels.</p>
<p>Impaired glucose tolerance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_9440e503-baf7-441c-991f-439bc85d32c3"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">The following serious adverse reactions are discussed elsewhere in the labeling:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> <span class="Italics">[see <a href="#LINK_bb7ceb11-60f8-401d-96f1-e2c3a6687b98">Boxed Warning</a>, <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Malignant Neoplasms <span class="Italics">[see <a href="#LINK_bb7ceb11-60f8-401d-96f1-e2c3a6687b98">Boxed Warning</a>, <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">Warnings and Precautions, (5.2)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_678d76ea-b8d4-4361-8915-76cb0eb365f0"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1        Clinical Trials Experience</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p>Adverse reactions reported with Lopreeza 1 mg/0.5 mg by investigators in the Phase 3 studies regardless of causality assessment are shown in Table 1.</p>
<p><span class="Bold">TABLE 1</span></p>
<p><span class="Bold">ALL TREATMENT-EMERGENT ADVERSE REACTIONS REGARDLESS OF RELATIONSHIP REPORTED AT A FREQUENCY OF ≥</span><span class="Bold"> 5 PERCENT WITH LOPREEZA 1 MG/0.5 MG</span></p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td> </td>
<td align="center" colspan="2">
<p class="First">Endometrial</p>
<p><span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">Hyperplasia</span> Study</p>
<p>(12-Months)</p>
</td>
<td align="center" colspan="2">
<p class="First">Vasomotor</p>
<p>Symptoms Study</p>
<p>(3-Months)</p>
</td>
<td align="center" colspan="2">
<p class="First"><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></p>
<p>Study</p>
<p>(2-Years) </p>
</td>
</tr>
<tr>
<td align="center"> </td>
<td align="center">
<p class="First">Lopreeza</p>
<p>1 mg/0.5 mg</p>
</td>
<td align="center"> 1 mg E<span class="Sub">2</span>
</td>
<td align="center">
<p class="First">Lopreeza</p>
<p>1 mg/0.5 mg</p>
</td>
<td align="center">Placebo</td>
<td align="center">
<p class="First">Lopreeza</p>
<p>1 mg/0.5 mg</p>
</td>
<td align="center">Placebo </td>
</tr>
<tr>
<td> </td>
<td align="center"> (n=295)</td>
<td align="center"> (n=296)</td>
<td align="center"> (n=29)</td>
<td align="center"> (n=34)</td>
<td align="center"> (n=47)</td>
<td align="center"> (n=48)</td>
</tr>
<tr>
<td>
<span class="Bold"><span class="Italics">Body as a Whole</span></span> </td>
<td> </td>
<td> </td>
<td> </td>
<td align="center"> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="center">6% </td>
<td align="center"> 5%</td>
<td align="center"> 3%</td>
<td align="center">3% </td>
<td align="center">6% </td>
<td align="center">4% </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center"> 16%</td>
<td align="center"> 16%</td>
<td align="center"> 17%</td>
<td align="center">18% </td>
<td align="center">11% </td>
<td align="center">6% </td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td align="center"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="Bold"><span class="Italics">Digestive System</span></span>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td align="center"> </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center"> 3%</td>
<td align="center"> 5%</td>
<td align="center">10% </td>
<td align="center">0% </td>
<td align="center">11% </td>
<td align="center">0% </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></td>
<td align="center"> 2%</td>
<td align="center"> 2%</td>
<td align="center">0% </td>
<td align="center">0%</td>
<td align="center">6% </td>
<td align="center">4% </td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="Bold"><span class="Italics">Nervous System</span></span>
</td>
<td> </td>
<td> </td>
<td> </td>
<td align="center"> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">6% </td>
<td align="center"> 4%</td>
<td align="center">3% </td>
<td align="center">3% </td>
<td align="center">0% </td>
<td align="center"> 8%</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span></td>
<td align="center"> 1%</td>
<td align="center"> 1%</td>
<td align="center">0% </td>
<td align="center"> 0%</td>
<td align="center">6% </td>
<td align="center"> 0%</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="Bold"><span class="Italics">Respiratory System</span></span>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td align="center"> 18%</td>
<td align="center">15% </td>
<td align="center">10%</td>
<td align="center">6% </td>
<td align="center">15% </td>
<td align="center">19% </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center"> 7%</td>
<td align="center"> 11%</td>
<td align="center">7%</td>
<td align="center"> 0%</td>
<td align="center">15% </td>
<td align="center">10% </td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="Bold"><span class="Italics">Metabolic and Nutritional</span></span>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increase</span></td>
<td align="center"> 0%</td>
<td align="center">0% </td>
<td align="center">0% </td>
<td align="center">0% </td>
<td align="center">9% </td>
<td align="center">6% </td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td align="center"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="Bold"><span class="Italics">Urogenital System</span></span>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast Pain</span></td>
<td align="center"> 24%</td>
<td align="center">10% </td>
<td align="center">21% </td>
<td align="center">0% </td>
<td align="center">17% </td>
<td align="center">8% </td>
</tr>
<tr>
<td> Post-Menopausal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></td>
<td align="center"> 5%</td>
<td align="center">15% </td>
<td align="center">10% </td>
<td align="center">3% </td>
<td align="center">11% </td>
<td align="center">0% </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">Uterine Fibroid</span></td>
<td align="center"> 5%</td>
<td align="center">4% </td>
<td align="center">0% </td>
<td align="center">0% </td>
<td align="center">4% </td>
<td align="center">8% </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian Cyst</span></td>
<td align="center"> 3%</td>
<td align="center">2% </td>
<td align="center">7% </td>
<td align="center">0% </td>
<td align="center">0% </td>
<td align="center">8% </td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="Bold"><span class="Italics">Resistance Mechanism</span></span>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">Infection Viral</span></td>
<td align="center"> 4%</td>
<td align="center">6% </td>
<td align="center">0% </td>
<td align="center">3% </td>
<td align="center">6% </td>
<td align="center">6% </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4080452" conceptname="Anogenital candidiasis">Moniliasis Genital</span></td>
<td align="center"> 4%</td>
<td align="center">7% </td>
<td align="center">0% </td>
<td align="center">0% </td>
<td align="center">6% </td>
<td align="center">0% </td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="Bold"><span class="Italics">Secondary Terms</span></span>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td align="center"> </td>
<td> </td>
</tr>
<tr>
<td> Injury Accidental</td>
<td align="center"> 4%</td>
<td align="center">3% </td>
<td align="center">3% </td>
<td align="center">0% </td>
<td align="center">17%* </td>
<td align="center">4%* </td>
</tr>
<tr class="Last">
<td> Other Events</td>
<td align="center"> 2%</td>
<td align="center">3% </td>
<td align="center">3% </td>
<td align="center"> 0%</td>
<td align="center">6%</td>
<td align="center">4% </td>
</tr>
</tbody>
</table>
<p>* including one upper extremity <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in each group</p>
<p>Adverse reactions reported with Lopreeza 0.5 mg/0.1 mg by investigators during the Phase 3 study regardless of causality assessment are shown in Table 2.</p>
<p><span class="Bold">TABLE 2</span></p>
<p><span class="Bold">ALL TREATMENT-EMERGENT ADVERSE REACTIONS REGARDLESS OF RELATIONSHIP REPORTED AT A FREQUENCY OF <span class="Bold">≥</span> 5 PERCENT WITH LOPREEZA 0.5 MG/0.1 MG</span> </p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td> </td>
<td align="center">
<p class="First">Lopreeza</p> 0.5 mg/0.1 mg </td>
<td align="center">Placebo </td>
</tr>
<tr>
<td> </td>
<td align="center"> (n=194)</td>
<td align="center"> (n=200)</td>
</tr>
<tr>
<td>
<span class="Bold"><span class="Italics">Body as a Whole</span></span> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="center"> 10%</td>
<td align="center">4% </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center"> 22%</td>
<td align="center">19%</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td align="center">5% </td>
<td align="center">4% </td>
</tr>
<tr>
<td> </td>
<td align="center"> </td>
<td> </td>
</tr>
<tr>
<td> <span class="Bold"><span class="Italics">Digestive System</span></span>
</td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">5% </td>
<td align="center">4% </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">6% </td>
<td align="center">6% </td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>
<span class="Bold"><span class="Italics">Respiratory System</span></span> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="center"> 21%</td>
<td align="center">18% </td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>
<span class="Bold"><span class="Italics">Urogenital System</span></span> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Endometrial thickening</td>
<td align="center"> 10%</td>
<td align="center">4% </td>
</tr>
<tr class="Last">
<td> <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal hemorrhage</span></td>
<td align="center"> 26%</td>
<td align="center">12% </td>
</tr>
</tbody>
</table>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_209c127c-becf-4acf-b7db-8b494d65a5da"></a><a name="section-6.2"></a><p></p>
<h2>
<span class="Bold">6</span>.<span class="Bold">2       Postmarketing Experience</span>
</h2>
<p class="First"><span class="Bold"> </span></p>
<p>The following adverse reactions have been identified during post-approval use of Lopreeza.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Genitourinary System</span></p>
<p>Changes in <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> pattern and abnormal <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> or flow; breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>; spotting; <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, increase in size of uterine leiomyomata; <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>; change in amount of cervical secretion; changes in cervical <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span>;  pre-menstrual-like syndrome; <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>-like syndrome; ovarian cancer; <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>; endometrial cancer.</p>
<p></p>
<p><span class="Italics">Breast</span></p>
<p><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span>, enlargement, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>; <span class="product-label-link" type="condition" conceptid="78804" conceptname="Fibrocystic disease of breast">fibrocystic breast</span> changes; breast cancer. </p>
<p></p>
<p><span class="Italics">Cardiovascular</span></p>
<p>Deep and superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>; <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>; <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; increase in blood pressure.</p>
<p></p>
<p><span class="Italics">Gastrointestinal</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; changes in appetite; <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>; <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>; increased incidence of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.   </p>
<p></p>
<p><span class="Italics">Skin</span></p>
<p><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span> that may persist when drug is discontinued; <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>; hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>; loss of scalp hair; <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>; <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>; <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>; <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p><span class="Italics">Eyes</span></p>
<p>Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, intolerance to contact lenses.</p>
<p></p>
<p><span class="Italics">Central Nervous System</span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>; <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; mood disturbances; <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>; exacerbation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>; <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.</p>
<p><span class="Italics">Miscellaneous</span></p>
<p>Increase or decrease in weight;  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>; changes in libido; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>; increased triglycerides; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>; anaphylactoid/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_502b69ea-bc62-44f2-99bf-3b1e2befd8e4"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Coadministration of estradiol with norethindrone acetate did not elicit any apparent influence on the pharmacokinetics of norethindrone acetate. Similarly, no relevant interaction of norethindrone acetate on the pharmacokinetics of estradiol was found within the NETA dose range investigated in a single dose study. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f4f5ea9a-d110-46fd-970e-12c745d74fa0"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">7.1       Metabolic Interactions</span></h2>
<p class="First"><span class="Bold"> </span></p>
<p><span class="Bold">Estradiol</span></p>
<p><span class="Italics">In-vitro</span> and <span class="Italics">in-vivo</span> studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4).  Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism.  Inducers of CYP3A4 such as St. John’s wort (<span class="Italics">Hypericum perforatum</span>) preparations, phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile.  Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and result in side effects.</p>
<p><span class="Bold">Norethindrone Acetate</span></p>
<p>Drugs or herbal products that induce or inhibit cytochrome P-450 enzymes, including CYP3A4, may decrease or increase the serum concentrations of norethindrone. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_d8fb27d1-edc0-46b8-9cc1-d87f6735066d"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_c7ddff79-330d-427b-b47b-400ef0464579"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold"> </span></p>
<p>Lopreeza should not be used during pregnancy <span class="Italics">[see <a href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">Contraindications (4)</a>]. </span>There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_0fcc4622-7beb-4aeb-bd07-c09345848be3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Lopreeza should not be used during lactation. Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. Detectable amounts of estrogen and progestin have been identified in the breast milk of women receiving estrogen plus progestin therapy. Caution should be exercised when Lopreeza is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_2a76746e-04aa-4ca6-8470-1aa0e68d79ac"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Lopreeza is not indicated in children. Clinical studies have not been conducted in the pediatric population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There have not been sufficient numbers of geriatric women involved in clinical studies utilizing Lopreeza to determine whether those over 65 years of age differ from younger subjects in their response to Lopreeza.</p>
<p><span class="Italics"><span class="Underline">The Women’s Health Initiative Studies</span></span></p>
<p>In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer in women greater than 65 years of age <span class="Italics">[see <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]</span>.</p>
<p>In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in women greater than 65 years of age <span class="Italics">[see <a href="#LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae">Clinical Studies (14.5)</a>]</span>.</p>
<p><span class="Italics"><span class="Underline">The Women’s Health Initiative Memory Study</span></span></p>
<p>In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women receiving estrogen plus progestin or estrogen-alone when compared to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics">[see <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">Warnings and Precautions (5.3)</a>, and <a href="#LINK_208f53fa-35e8-4739-a446-489cbf46d4dd">Clinical Studies (14.6)</a>]</span>.</p>
<p>Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Sup">8 </span><span class="Italics">[see <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">Warnings and Precautions (5.3)</a>, and <a href="#LINK_208f53fa-35e8-4739-a446-489cbf46d4dd">Clinical Studies (14.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bc0d2439-6b25-4066-b14b-adaa13cca720"></a><a name="section-8.5"></a><p></p>
<h2><span class="Bold">8.6     <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h2>
<p class="First"><span class="Bold"> </span></p>
<p>The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of Lopreeza has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_df7edcc3-4a7b-498d-af25-c3dae0154867"></a><a name="section-8.6"></a><p></p>
<h2><span class="Bold">8.7     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h2>
<p class="First"><span class="Bold"> </span></p>
<p>The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of Lopreeza has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_7672321b-456b-49d1-95e6-3b804a643ebe"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage of estrogen plus progestin may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in women. Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> consists of discontinuation of Lopreeza therapy with institution of appropriate symptomatic care.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_94dfdaa6-3893-42c2-9260-ca4a11462f2f"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Lopreeza 1 mg/0.5 mg is a single tablet for oral administration containing 1 mg of estradiol and 0.5 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose and triacetin. </p>
<p>Lopreeza0.5 mg/0.1 mg is a single tablet for oral administration containing 0.5 mg of estradiol and 0.1 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), hydroxypropylcellulose, talc, magnesium stearate, hypromellose and triacetin.</p>
<p>Estradiol (E<span class="Sub">2</span>), an estrogen, is a white or almost white crystalline powder. Its chemical name is estra-1, 3, 5 (10)-triene-3, 17β-diol hemihydrate with the empirical formula of C<span class="Sub">18</span>H<span class="Sub">24</span>O<span class="Sub">2</span>,½ H<span class="Sub">2</span>O and a molecular weight of 281.4.  The structural formula of E<span class="Sub">2</span> is as follows:</p>
<p><img alt="estradiol chem structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-1.jpg"> </p>
<p><span class="Bold">Estradiol</span></p>
<p>Norethindrone acetate (NETA), a progestin, is a white or yellowish-white crystalline powder. Its chemical name is 17β-acetoxy-19-nor-17α -pregn-4-en-20-yn-3-one with the empirical formula of C<span class="Sub">22</span>H<span class="Sub">28</span>O<span class="Sub">3</span> and molecular weight of 340.5.  The structural formula of NETA is as follows:</p>
<p><img alt="noreth acetate chem structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-2.jpg"> </p>
<p><span class="Bold">Norethindrone Acetate</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_bccb04cc-3991-4ea2-b6f4-04a6afd0b8f3"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_f1abae1d-7871-43d7-bbb1-77ffe4b1ffb5"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics.  Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.</p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle.  After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues.  Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. </p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues.  To date, two estrogen receptors have been identified.  These vary in proportion from tissue to tissue.</p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and FSH through a negative feedback mechanism.  Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.</p>
<p>Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, and central nervous system.     </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_341097fb-f403-4324-b506-0e5f01fc8f3a"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">There are no pharmacodynamic data known for Lopreeza tablets.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_40da22ab-9880-419c-aac4-3222230c217b"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"> </span></p>
<p><span class="Bold">Absorption</span></p>
<p><span class="Bold">Estradiol</span></p>
<p>Estradiol is absorbed through the gastrointestinal tract.  Following oral administration of Lopreeza tablets, peak plasma estradiol concentrations are reached within 5 to 8 hours.  The oral bioavailability of estradiol following administration of Lopreeza 1 mg/0.5 mg when compared to a combination oral solution is 53%.  Administration of Lopreeza 1 mg/0.5 mg with food did not modify the bioavailability of estradiol.</p>
<p><span class="Bold">Norethindrone Acetate</span></p>
<p>After oral administration, norethindrone acetate is absorbed and transformed to norethindrone.  Norethindrone reaches a peak plasma concentration within 0.5 to 1.5 hours after the administration of Lopreeza tablets.  The oral bioavailability of norethindrone following administration of Lopreeza 1 mg/0.5 mg when compared to a combination oral solution is 100%.  Administration of Lopreeza 1 mg/0.5 mg with food increases norethindrone AUC<span class="Sub">0-72</span> by 19% and decreases C<span class="Sub">max</span> by 36%.</p>
<p>The pharmacokinetic parameters of estradiol (E<span class="Sub">2</span>), estrone (E<span class="Sub">1</span>), and norethindrone (NET) following oral administration of 1 Lopreeza 1 mg/0.5 mg or 2 Lopreeza 0.5 mg/0.1 mg tablet(s) to healthy postmenopausal women are summarized in Table 3.</p>
<p><span class="Bold">TABLE 3</span></p>
<p><span class="Bold">PHARMACOKINETIC PARAMETERS AFTER ADMINISTRATION OF </span></p>
<p><span class="Bold">1 TABLET OF </span><span class="Bold">LOPREEZA 1 MG/0.5 MG OR 2 TABLETS OF LOPREEZA 0.5 MG/0.1 MG </span></p>
<p><span class="Bold">TO HEALTHY POSTMENOPAUSAL WOMEN</span> </p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td> </td>
<td>
<p class="First">1 x Lopreeza</p>
<p>1 mg/0.5 mg</p>
<p>(n=24) </p>
</td>
<td> <p class="First">2 x Lopreeza</p>
<p>0.5 mg/0.1 mg</p>
<p>(n=24)</p>
</td>
</tr>
<tr>
<td> </td>
<td> Mean<span class="Sup">a</span> (%CV)<span class="Sup">b</span>
</td>
<td> Mean<span class="Sup">a</span> (%CV)<span class="Sup">b</span>
</td>
</tr>
<tr>
<td>
<span class="Bold">Estradiol<span class="Sup">c</span> (E<span class="Sub">2</span>)</span> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> AUC<span class="Sub">0-t</span> (pg/mL*h)</td>
<td> 766.5 (48)</td>
<td> 697.3 (53)</td>
</tr>
<tr>
<td> C<span class="Sub">max</span>(pg/mL) </td>
<td> 26.8 (36)</td>
<td> 26.5 (37)</td>
</tr>
<tr>
<td> t<span class="Sub">max</span>(h): median (range)</td>
<td> 6.0 (0.5-16.0)</td>
<td> 6.5 (0.5-16.0)</td>
</tr>
<tr>
<td> t<span class="Sub">1/2</span>(h)<span class="Sup">d </span>
</td>
<td> 14.0<span class="Sup">e</span> (29)</td>
<td> 14.5<span class="Sup">f</span> (27)</td>
</tr>
<tr>
<td> <span class="Bold">Estrone<span class="Sup">c</span> (E<span class="Sub">1</span>)</span>
</td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> AUC<span class="Sub">0-t</span> (pg/mL*h) </td>
<td> 4469.1 (48)</td>
<td> 4506.4 (44)</td>
</tr>
<tr>
<td> C<span class="Sub">max</span>(pg/mL)</td>
<td> 195.5 (37)</td>
<td> 199.5 (30)</td>
</tr>
<tr>
<td> t<span class="Sub">max</span>(h): median (range)</td>
<td> 6.0 (1.0-9.0)</td>
<td> 6.0 (2.0-9.0)</td>
</tr>
<tr>
<td> t<span class="Sub">1/2</span>(h)<span class="Sup">d</span>
</td>
<td> 10.7 (44)<span class="Sup">g</span>
</td>
<td> 11.8 (25)<span class="Sup">g</span>
</td>
</tr>
<tr>
<td> <span class="Bold">Norethindrone (NET)</span>
</td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> AUC<span class="Sub">0-t</span> (pg/mL*h) </td>
<td> 21043 (41)</td>
<td> 8407.2 (43)</td>
</tr>
<tr>
<td> C<span class="Sub">max</span>(pg/mL)</td>
<td> 5249.5 (47)</td>
<td> 2375.4 (41)</td>
</tr>
<tr>
<td> t<span class="Sub">max</span>(h) : median (range)</td>
<td> 0.7 (0.7-1.25)</td>
<td> 0.8 (0.7-1.3)</td>
</tr>
<tr class="Last">
<td> t<span class="Sub">1/2</span>(h) </td>
<td> 9.8 (32)<span class="Sup">h</span>
</td>
<td> 11.4 (36)<span class="Sup">i</span>
</td>
</tr>
</tbody>
</table>
<p>AUC = area under the curve, 0 – last quantifiable sample</p>
<p>C<span class="Sub">max</span> = maximum plasma concentration, </p>
<p>t<span class="Sub">max</span> = time at maximum plasma concentration, </p>
<p>t<span class="Sub">1/2</span> = half-life,</p>
<p><span class="Sup">a </span>geometric mean; <span class="Sup">b </span>geometric % coefficient of variation; <span class="Sup">c </span>baseline unadjusted data; <span class="Sup">d</span> baseline unadjusted data; <span class="Sup">e </span>n=18; <span class="Sup">f </span>n=16; </p>
<p><span class="Sup">g  </span>n=13; <span class="Sup">h</span> n=22; <span class="Sup">i </span>n=21</p>
<p> Following continuous dosing with once-daily administration of Lopreeza 1 mg/0.5 mg,serum concentrations of estradiol, estrone, and norethindrone reached steady-state within two weeks with an accumulation of 33 to 47% above concentrations following single dose administration.  Unadjusted circulating concentrations of E<span class="Sub">2</span>, E<span class="Sub">1</span>, and NET during Lopreeza 1 mg/0.5 mg treatment at steady state (dosing at time 0) are provided in Figures 1a and 1b. </p>
<p><span class="Bold">Figure 1a: Mean Baseline-Uncorrected Estradiol and Estrone Serum Concentration-Time Profiles Following Multiple Doses of Lopreeza 1 mg/0.5 mg (N=24)</span></p>
<p><img alt="figure 1a" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-3.jpg"> </p>
<p><span class="Bold">Figure 1b: Mean Baseline-Uncorrected Norethindrone Serum Concentration-Time Profile Following Multiple Doses of Lopreeza 1 mg/0.5 mg (N=24)</span></p>
<p><img alt="figure 1b" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-4.jpg"> </p>
<p><span class="Underline">Distribution</span></p>
<p><span class="Bold">Estradiol</span></p>
<p>The distribution of exogenous estrogens is similar to that of endogenous estrogens.  Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs.  Estradiol circulates in the blood bound to SHBG (37%) and to albumin (61%), while only approximately 1 to 2% is unbound.  </p>
<p><span class="Bold">Norethindrone Acetate</span></p>
<p>Norethindrone also binds to a similar extent to SHBG (36%) and to albumin (61%).</p>
<p><span class="Bold">Metabolism </span></p>
<p><span class="Bold">Estradiol</span>  </p>
<p>Exogenous estrogens are metabolized in the same manner as endogenous estrogens.  Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions.  These transformations take place mainly in the liver.  Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite.  Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption.  In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.  </p>
<p><span class="Bold">Norethindrone Acetate  </span></p>
<p>The most important metabolites of norethindrone are isomers of 5α-dihydro-norethindrone and tetrahydro-norethindrone, which are excreted mainly in the urine as sulfate or glucuronide conjugates.  </p>
<p><span class="Underline">Excretion</span></p>
<p><span class="Underline">Estradiol</span></p>
<p>Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.  The half-life of estradiol following single dose administration of Lopreeza 1 mg/0.5 mg is 12 to 14 hours.  </p>
<p><span class="Bold">Norethindrone Acetate</span></p>
<p>The terminal half-life of norethindrone is about 8 to 11 hours.</p>
<p><span class="Underline"><span class="Italics">Use in Specific Populations </span></span></p>
<p>No pharmacokinetic studies were conducted in specific populations, including women with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_5daa79e6-a212-4003-bec5-c4661f04ac51"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_de7b6a6c-102a-443a-8563-e9fb72cae2d9"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_995374a6-9348-42d8-aeae-912d8e71b14b"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_52c7dd07-f245-4888-9239-d01f2b2818f2"></a><a name="section-13.1"></a><p></p>
<h2><span class="Bold">14.1     Effects on Vasomotor Symptoms</span></h2>
<p class="First"><span class="Bold"> </span></p>
<p>In a 12-week randomized clinical trial involving 92 subjects, Lopreeza 1 mg/0.5 mg was compared to 1 mg of estradiol and to placebo.  The mean number and intensity of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> were significantly reduced from baseline to week 4 and 12 in both the Lopreeza 1 mg/0.5 mg and the 1 mg estradiol group compared to placebo (see Figure 2).</p>
<p><span class="Bold">Figure 2</span></p>
<p><span class="Bold">Mean Weekly Number of Moderate and Severe Hot<br>  Flushes in a 12-Week Study</span></p>
<p> <img alt="figure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-5.jpg"></p>
<p>In a study conducted in Europe a total of 577 postmenopausal women were randomly assigned to either Lopreeza 0.5 mg/0.1 mg, 0.5 mg E<span class="Sub">2</span>/0.25 mg NETA, or placebo for 24 weeks of treatment.  The mean number and severity of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> were significantly reduced at week 4 and week 12 in the Lopreeza 0.5 mg/0.1 mg (see Figure 3) and 0.5 mg E<span class="Sub">2</span>/0.25 mg NETA groups compared to placebo.</p>
<p><span class="Bold">Figure 3</span></p>
<p><span class="Bold">Mean Number of Moderate to Severe Hot</span></p>
<p><span class="Bold">Flushes for Weeks 0 Through 12</span></p>
<p><img alt="figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-6.jpg"> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_107a759a-071f-498b-a745-486e6123a22a"></a><a name="section-13.2"></a><p></p>
<h2><span class="Bold">14.2     Effects on the Endometrium</span></h2>
<p class="First">Lopreeza 1 mg/0.5 mg reduced the incidence of estrogen-induced <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> at 1 year in a randomized, controlled clinical trial.  This trial enrolled 1,176 subjects who were randomized to one of 4 arms:  1 mg estradiol unopposed (n=296), 1 mg E<span class="Sub">2</span> + 0.1 mg NETA (n=294), 1 mg E<span class="Sub">2</span> + 0.25 mg NETA (n=291), and Lopreeza 1 mg/0.5 mg (n=295).  At the end of the study, endometrial biopsy results were available for 988 subjects. The results of the 1 mg estradiol unopposed arm compared to Lopreeza 1 mg/0.5 mg are shown in Table 4.</p>
<p><span class="Bold"> </span></p>
<p><span class="Bold">TABLE 4</span></p>
<p><span class="Bold">INCIDENCE OF <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">ENDOMETRIAL HYPERPLASIA</span> WITH UNOPPOSED ESTRADIOL AND LOPREEZA 1 MG/0.5 MG IN A 12-MONTH STUDY </span>  </p>
<table>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td> </td>
<td><p class="First">1 mg E<span class="Sub">2</span><br>(n=296) </p></td>
<td>
<p class="First">Lopreeza</p>
<p>1 mg E<span class="Sub">2</span>/0.5 mg<br> NETA<br>(n=295) </p>
</td>
<td> <p class="First">1 mg E<span class="Sub">2</span>/0.25 mg <br>NETA<br>(n=291 )</p>
</td>
<td><p class="First">1 mg E<span class="Sub">2</span>/0.1 mg <br>NETA <br>(n=294 ) </p></td>
</tr>
<tr>
<td>No. of subjects with histological evaluation at the end of the study</td>
<td align="center"> 247</td>
<td align="center"> 241</td>
<td align="center"> 251</td>
<td align="center"> 249</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr class="Last">
<td>No. (%) of subjects with <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> at the end of the study </td>
<td align="center"> 36 (14.6%)</td>
<td align="center"> 1 (0.4%)</td>
<td align="center"> 1 (0.4%)</td>
<td align="center"> 2 (0.8%)</td>
</tr>
</tbody>
</table>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_aec1ddab-af2e-4bad-9b02-a4528b1b534a"></a><a name="section-13.3"></a><p></p>
<h2><span class="Bold">14.3     Effects on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span> or Spotting</span></h2>
<p class="First"><span class="Bold"> </span></p>
<p>During the initial months of therapy, irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting occurred with Lopreeza 1 mg/0.5 mg treatment.  However, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tended to decrease over time, and after 12 months of treatment with Lopreeza 1 mg/0.5 mg, about 86 percent of women were amenorrheic (see Figure 4).</p>
<p><span class="Bold">Figure 4</span></p>
<p><span class="Bold">Patients Treated with Lopreeza 1 mg/0.5 mg with Cumulative <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> over Time</span></p>
<p><span class="Bold">Percentage of Women with no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> or Spotting at any Cycle Through Cycle 13</span></p>
<p><span class="Bold">Intent to Treat Population, LOCF</span></p>
<p><span class="Bold"><img alt="figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-7.jpg">   </span></p>
<p>Note:  the percentage of patients who were amenorrheic in a given cycle and through cycle 13 is shown.  If data were missing, the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> value from the last reported day was carried forward (LOCF).</p>
<p>In the clinical trial with Lopreeza 0.5 mg/0.1 mg, 88 percent of women were amenorrheic after 6 months of treatment (See Figure 5).</p>
<p><span class="Bold">Figure 5</span></p>
<p><span class="Bold">Patients Treated with Lopreeza 0.5 mg/0.1 mg with</span></p>
<p><span class="Bold">Cumulative <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> over Time</span></p>
<p><span class="Bold">Percentage of Women with no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> or Spotting at any</span></p>
<p><span class="Bold">Cycle Through Cycle 6, Intent to Treat Population, LOCF</span></p>
<p><span class="Bold"><img alt="figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-8.jpg"> </span></p>
<p><span class="Bold"> </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fab843c9-0d00-4a57-b64e-1f91f68accbb"></a><a name="section-13.4"></a><p></p>
<h2><span class="Bold">14.4     Effects on Bone Mineral Density</span></h2>
<p class="First"><span class="Bold"> </span></p>
<p>The results of two randomized, multicenter, calcium-supplemented (500-1000 mg per day), placebo-controlled, 2 year clinical trials have shown that Lopreeza 1 mg/0.5 mg and estradiol 0.5 mg are effective in preventing bone loss in postmenopausal women.  A total of 462 postmenopausal women with intact uteri and baseline BMD values for lumbar spine within 2 standard deviations of the mean in healthy young women (T-score &gt; -2.0) were enrolled.  In a US trial, 327 postmenopausal women (mean time from <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> 2.5 to 3.1 years) with a mean age of 53 years were randomized to 7 groups (0.25 mg, 0.5 mg, and 1 mg of estradiol alone, 1 mg estradiol with 0.25 mg norethindrone acetate, 1 mg estradiol with 0.5 mg norethindrone acetate, and 2 mg estradiol with 1 mg norethindrone acetate, and placebo.)  In a European trial (EU trial), 135 postmenopausal women (mean time from <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> 8.4 to 9.3 years) with a mean age of 58 years were randomized to 1 mg estradiolwith 0.25 mg norethindrone acetate, 1 mg estradiol with 0.5 mg norethindrone acetate, andplacebo.  Approximately 58 percent and 67 percent of the randomized subjects in the two clinical trials, respectively, completed the two clinical trials.  BMD was measured using dual-energy x-ray absorptiometry (DXA).</p>
<p>A summary of the results comparing Lopreeza 1 mg/0.5 mg and estradiol 0.5 mg to placebo from the two prevention trials is shown in Table 5.</p>
<p><span class="Bold">TABLE 5</span></p>
<p><span class="Bold">PERCENTAGE CHANGE (MEAN </span><span class="Bold">±</span><span class="Bold"> SD) IN BONE MINERAL DENSITY (BMD) FOR </span></p>
<p><span class="Bold">LOPREEZA 1 MG/0.5 MG AND 0.5 MG E<span class="Sub">2</span></span><span class="Sup">†</span></p>
<p><span class="Bold">(Intent to Treat Analysis, Last Observation Carried Forward)</span></p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td> </td>
<td align="center" colspan="3"> US Trial</td>
<td align="center" colspan="2">EU Trial  </td>
</tr>
<tr>
<td> </td>
<td align="center">Placebo<br> (n=37)</td>
<td align="center">
<p class="First"> 0.5 mg E<span class="Sub">2</span><span class="Sup">†</span></p>
<p>(n=31)</p>
</td>
<td align="center">
<p class="First">Lopreeza</p>
<p>1 mg/0.5 mg <br> (n=37)</p>
</td>
<td align="center">
<p class="First">Placebo</p>
<p>(n=40)</p>
</td>
<td align="center">
<p class="First">Lopreeza</p>
<p>1 mg/0.5 mg<br> (n=38)</p>
</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Lumbar spine</td>
<td>-2.1 ± 2.9 </td>
<td> 2.3 ± 2.8 *</td>
<td>3.8 ± 3.0 * </td>
<td>-0.9 ± 4.0 </td>
<td>5.4 ± 4.8 * </td>
</tr>
<tr>
<td> Femoral neck</td>
<td> -2.3 ± 3.4</td>
<td> 0.3 ± 2.9 **</td>
<td> 1.8 ± 4.1 *</td>
<td> -1.0 ± 4.6</td>
<td> 0.7 ± 6.1</td>
</tr>
<tr class="Last">
<td>Femoral trochanter </td>
<td> -2.0 ± 4.3</td>
<td> 1.7 ± 4.1***</td>
<td> 3.7 ± 4.3 *</td>
<td> 0.8 ± 6.9</td>
<td> 6.3 ± 7.6 *</td>
</tr>
</tbody>
</table>
<p>US= United States, EU = European</p>
<p><span class="Sup">† </span>While Lopreeza 0.5 mg/0.1 mg was not directly studied in these trials, the US trial showed that addition of NETA to estradiol enhances the effect on BMD; therefore the BMD changes expected from treatment with Lopreeza 0.5 mg/0.1 mg should be at least as great as observed with estradiol 0.5 mg.<br> * Significantly (p&lt;0.001) different from placebo</p>
<p>** Significantly (p&lt;0.007) different from placebo</p>
<p>***Significantly (p&lt;0.002) different from placebo</p>
<p>The overall difference in mean percentage change in BMD at the lumbar spine in the US trial (1000 mg per day calcium) between Lopreeza 1 mg/0.5 mg and placebo was 5.9 percent and between estradiol 0.5 mg and placebo was 4.4 percent.  In the European trial (500 mg per day calcium), the overall difference in mean percentage change in BMD at the lumbar spine was 6.3 percent.  Lopreeza 1 mg/0.5 mg and estradiol 0.5 mg also increased BMD at the femoral neck and femoral trochanter compared to placebo.  The increase in lumbar spine BMD in the US and European clinical trials for Lopreeza 1 mg/0.5 mg and estradiol 0.5 mg is displayed in Figure 6. </p>
<p><span class="Bold">Figure 6</span></p>
<p><span class="Bold">Percentage Change in Bone Mineral Density (BMD) ± SEM of the Lumbar Spine (L1-L4) for </span></p>
<p><span class="Bold">Lopreeza 1 mg/0.5 mg and Estradiol 0.5 mg</span></p>
<p><span class="Bold">(Intent to Treat Analysis with Last Observation Carried Forward)</span></p>
<p><span class="Bold"><img alt="figure6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-9.jpg"></span></p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5e107b7a-a225-40dc-a95c-1e3b634dfcae"></a><a name="section-13.5"></a><p></p>
<h2><span class="Bold">14.5     Women’s Health Initiative Studies</span></h2>
<p class="First">The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as the primary adverse outcome. A “global index? included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other cause.  These substudies did not evaluate the effects of CE plus MPA or CE-alone on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>.</p>
<p><span class="Italics">WHI Estrogen Plus Progestin Substudy</span></p>
<p>The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the “global index.?  The absolute excess risk of events included in the “global index? was 19 per 10,000 women-years.   </p>
<p>For those outcomes included in the WHI “global index,? that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>.</p>
<p>Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in Table 6. These results reflect centrally adjudicated data after an average follow-up of 5.6 years.</p>
<p><span class="Bold">Table 6: Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years<span class="Sup">a,b</span></span> </p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td>Event  </td>
<td> Relative Risk <br> CE/MPA versus Placebo <br> (95% nCI<span class="Sup">c</span>) </td>
<td>CE/MPA<br> n = 8,506  </td>
<td>Placebo<br> n = 8,102  </td>
</tr>
<tr>
<td class="Botrule"> </td>
<td class="Botrule"> </td>
<td class="Botrule" colspan="2"> Absolute Risk per 10,000 Women-Years</td>
</tr>
<tr>
<td> CHD events </td>
<td> 1.23 (0.99-1.53) </td>
<td> 41</td>
<td> 34</td>
</tr>
<tr>
<td>     <span class="Italics">Non-fatal MI</span>
</td>
<td> <span class="Italics">1.28 (1.00-1.63)</span>
</td>
<td> <span class="Italics">31</span>
</td>
<td> <span class="Italics">25</span>
</td>
</tr>
<tr>
<td>     <span class="Italics">CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>
</td>
<td> <span class="Italics">1.10 (0.70-1.75)</span>
</td>
<td><span class="Italics"> 8</span></td>
<td><span class="Italics"> 8</span></td>
</tr>
<tr>
<td> All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span></td>
<td> 1.31 (1.03–1.68)</td>
<td> 33</td>
<td> 25</td>
</tr>
<tr>
<td> <span class="Italics">    <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span> </span>
</td>
<td> <span class="Italics">1.44 (1.09–1.90) </span>
</td>
<td><span class="Italics"> 26</span></td>
<td> <span class="Italics">18</span>
</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><span class="Sup">d</span>
</td>
<td> 1.95 (1.43–2.67)</td>
<td> 26</td>
<td> 13</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></td>
<td> 2.13 (1.45–3.11)</td>
<td> 18</td>
<td> 8</td>
</tr>
<tr>
<td> Invasive breast cancer<span class="Sup">e</span>
</td>
<td>1.24 (1.01–1.54)</td>
<td> 41</td>
<td> 33</td>
</tr>
<tr>
<td> Colorectal cancer</td>
<td> 0.61 (0.42–0.87)</td>
<td> 10</td>
<td> 16</td>
</tr>
<tr>
<td> Endometrial cancer<span class="Sup">d</span>
</td>
<td> 0.81 (0.48–1.36)</td>
<td> 6</td>
<td> 7</td>
</tr>
<tr>
<td> Cervical cancer<span class="Sup">d</span>
</td>
<td> 1.44 (0.47–4.42)</td>
<td> 2</td>
<td> 1</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span> </td>
<td> 0.67 (0.47–0.96)</td>
<td> 11</td>
<td> 16</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><span class="Sup">d</span>
</td>
<td> 0.65 (0.46–0.92)</td>
<td> 11</td>
<td> 17</td>
</tr>
<tr>
<td> Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">d</span>
</td>
<td> 0.71 (0.59–0.85)</td>
<td> 44</td>
<td> 62</td>
</tr>
<tr>
<td class="Botrule"> Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">d</span>
</td>
<td class="Botrule"> 0.76 (0.69–0.83)</td>
<td class="Botrule"> 152</td>
<td class="Botrule"> 199</td>
</tr>
<tr>
<td class="Botrule"> Overall Mortality<span class="Sup">f</span>
</td>
<td class="Botrule"> 1.00 (0.83-1.19)</td>
<td class="Botrule"> 52</td>
<td class="Botrule"> 52</td>
</tr>
<tr class="Last">
<td class="Botrule"> Global Index<span class="Sup">g</span>
</td>
<td class="Botrule"> 1.13 (1.02-1.25)</td>
<td class="Botrule"> 184</td>
<td class="Botrule"> 165</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a  </span>Adapted from numerous WHI publications. WHI publications can be viewed at <a href="#whi">www.nhlbi.nih.gov/whi</a>. </p>
<p><span class="Sup">b</span> Results are based on centrally adjudicated data. </p>
<p><span class="Sup">c</span> Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</p>
<p><span class="Sup">d</span> Not included in “global index?.</p>
<p><span class="Sup">e</span>Includes metastatic and non-metastatic breast cancer, with the exception of <span class="Italics">in situ</span> breast cancer. </p>
<p><span class="Sup">f</span> All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</p>
<p><span class="Sup">g</span> A subset of the events was combined in a “global index? defined as the earliest occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes.</p>
<p>Timing of the initiation of estrogen plus progestin therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for overall mortality <span class="Italics">[hazard ratio (HR) 0.69 (95 percent CI, 0.44-1.07)].   </span></p>
<p><span class="Italics"><span class="Underline">WHI Estrogen-Alone Substudy</span></span></p>
<p>The WHI estrogen-alone substudy was stopped early because an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints.  </p>
<p> Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow-up of 7.1 years, are presented in Table 7. </p>
<p><span class="Bold">Table 7: Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI<span class="Sup">a</span></span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td>Event  </td>
<td>Relative Risk <br> CE versus Placebo<br> (95% nCI<span class="Sup">b</span>)  </td>
<td>CE<br> n = 5,310 </td>
<td> Placebo<br> n = 5,429 </td>
</tr>
<tr>
<td class="Botrule"> </td>
<td class="Botrule"> </td>
<td class="Botrule" colspan="2"> Absolute Risk per 10,000 Women-Years</td>
</tr>
<tr>
<td> CHD events<span class="Sup">c</span>
</td>
<td> 0.95 (0.78–1.16)</td>
<td> 54</td>
<td>57 </td>
</tr>
<tr>
<td>      <span class="Italics">Non-fatal MI<span class="Sup">c</span></span>
</td>
<td> <span class="Italics">0.91 (0.73–1.14)</span>
</td>
<td> <span class="Italics">40</span>
</td>
<td><span class="Italics"> 43</span></td>
</tr>
<tr>
<td>      <span class="Italics">CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><span class="Sup">c</span></span>
</td>
<td> <span class="Italics">1.01(0.71–1.43)</span>
</td>
<td><span class="Italics"> 16</span></td>
<td><span class="Italics"> 16</span></td>
</tr>
<tr>
<td> All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span><span class="Sup">c</span>
</td>
<td> 1.33 (1.05-1.68) </td>
<td> 45</td>
<td> 33</td>
</tr>
<tr>
<td> <span class="Italics">       <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span><span class="Sup">b</span></span>
</td>
<td> <span class="Italics">1.55 (1.19 – 2.01)</span>
</td>
<td><span class="Italics"> 38</span></td>
<td><span class="Italics"> 25</span></td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><span class="Sup">c,d</span>
</td>
<td> 1.47 (1.06–2.06)</td>
<td> 23</td>
<td> 15</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span><span class="Sup">c</span>
</td>
<td> 1.37 (0.90–2.07)</td>
<td> 14</td>
<td> 10</td>
</tr>
<tr>
<td> Invasive breast cancer<span class="Sup">c</span>
</td>
<td> 0.80 (0.62–1.04)</td>
<td> 28</td>
<td> 34</td>
</tr>
<tr>
<td> Colorectal cancer<span class="Sup">e</span>
</td>
<td> 1.08 (0.75–1.55)</td>
<td> 17</td>
<td> 16</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span><span class="Sup">c</span>
</td>
<td> 0.65 (0.45–0.94)</td>
<td> 12</td>
<td> 19</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><span class="Sup">c,d</span>
</td>
<td> 0.64 (0.44-0.93) </td>
<td> 11</td>
<td> 18</td>
</tr>
<tr>
<td> Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">c,d</span>
</td>
<td> 0.58 (0.47-0.72)</td>
<td> 35</td>
<td> 59</td>
</tr>
<tr>
<td> Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><span class="Sup">c,d</span>
</td>
<td> 0.71 (0.64-0.80) </td>
<td> 144</td>
<td> 197</td>
</tr>
<tr>
<td class="Botrule"> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to other causes<span class="Sup">e,f</span>
</td>
<td class="Botrule"> 1.08 (0.88–1.32)</td>
<td class="Botrule"> 53</td>
<td class="Botrule"> 50</td>
</tr>
<tr>
<td class="Botrule"> Overall mortality<span class="Sup">c,d </span>
</td>
<td class="Botrule"> 1.04 (0.88–1.22)</td>
<td class="Botrule"> 79</td>
<td class="Botrule"> 75</td>
</tr>
<tr class="Last">
<td class="Botrule"> Global Index<span class="Sup">g</span>
</td>
<td class="Botrule"> 1.02 (0.92–1.13)</td>
<td class="Botrule"> 206</td>
<td class="Botrule"> 201</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span> Adapted from numerous WHI publications. WHI publications can be viewed at <a href="#whi">www.nhlbi.nih.gov/whi</a>.</p>
<p><span class="Sup">b</span> Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</p>
<p><span class="Sup">c </span>Results are based on centrally adjudicated data for an average follow-up of 7.1 years.</p>
<p><span class="Sup">d </span>Not included in “global index?. </p>
<p><span class="Sup">e</span> Results are based on an average follow-up of 6.8 years.</p>
<p><span class="Sup">f </span>All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</p>
<p><span class="Sup">g </span>A subset of the events was combined in a “global index,? defined as the earliest occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes.</p>
<p>For those outcomes included in the WHI “global index? that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while the absolute risk reduction per 10,000 women-years was 7 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>.<span class="Sup">9</span>  The absolute excess risk of events included in the “global index? was a non-significant 5 events per 10,000 women-years.  There was no difference between the groups in terms of all-cause mortality.  </p>
<p>No overall difference for primary CHD events (nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow up of 7.1 years.</p>
<p>Centrally adjudicated results for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in distribution of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> subtype or severity, including fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, in women receiving CE-alone compared to placebo. Estrogen-alone increased the risk for <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>, and this excess risk was present in all subgroups of women examined.<span class="Sup">10</span></p>
<p> Timing of the initiation of estrogen-alone therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen-alone substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD <span class="Italics">[HR 0.63 (95 percent CI, 0.36-1.09)]</span> and overall mortality <span class="Italics">[HR 0.71 (95 percent CI, 0.46-1.11)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_208f53fa-35e8-4739-a446-489cbf46d4dd"></a><a name="section-13.6"></a><p></p>
<h2>
<span class="Bold">14.6 </span><span class="Bold">Women’s Health Initiative Memory Study</span>
</h2>
<p class="First">The WHIMS estrogen plus progestin ancillary study of WHI enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age, 35 percent were 70 to 74 years of age, 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to placebo.</p>
<p>After an average follow-up of 4 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included Alzheimer’s disease (AD), <span class="product-label-link" type="condition" conceptid="379778" conceptname="Multi-infarct dementia">vascular dementia</span> (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see <span class="Italics"><a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">Warnings and Precautions (</a></span><span class="Italics"><a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">5.3</a></span><span class="Italics"><a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">)</a></span></span><span class="Italics">, and <span class="Italics"><a href="#LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">Use in Specific Populations (</a></span><span class="Italics"><a href="#LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">8.5</a></span><span class="Italics"><a href="#LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">)</a></span></span><span class="Italics">].</span></p>
<p>The WHIMS estrogen-alone ancillary study of WHI study enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age (45 percent were 65 to 69 years of age, 36 percent were 70 to 74 years of age, 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to placebo.</p>
<p>After an average follow-up of 5.2 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included AD, VaD and mixed types (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">Warnings and Precautions (5.3)</a>, and <span class="Italics"><a href="#LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">Use in Specific Populations(8.5)</a></span></span><span class="Italics">]</span>.</p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 percent CI, 1.19-2.60). Differences between groups became apparent in the first year of treatment.  It is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">Warnings and Precautions (5.3)</a>, and <a href="#LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">Use in Specific Populations (8.5)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_07cda5ec-b313-410d-83b8-05a139869fc8"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic">
<li>Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span>. <span class="Italics">JAMA</span>. 2007;297:1465-1477.</li>
<li>Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. <span class="Italics">Arch Int Med</span>. 2006;166:357-365.</li>
<li>Cushman M, et al. Estrogen Plus Progestin and Risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span>. <span class="Italics">JAMA</span>. 2004;292:1573-1580.</li>
<li>Curb JD, et al. <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span> and Conjugated Equine Estrogen in Women Without a Uterus. <br><span class="Italics">Arch Int Med</span>. 2006;166:772-780.</li>
<li>Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. <span class="Italics">JAMA</span>. 2003;289:3234-3253.</li>
<li>Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. <span class="Italics">JAMA</span>. 2006;295:1647-1657.</li>
<li>Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. <span class="Italics">JAMA</span>. 2003;290:1739-1748. </li>
<li>Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> and Mild <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">Cognitive Impairment</span> in Postmenopausal Women.<span class="Italics"> JAMA</span>. 2004;291:2947-2958.</li>
<li>Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> and BMD in Postmenopausal Women With Hysterectomy: Results From the Women’s Health Initiative Randomized Trial.<span class="Italics"> J Bone Miner Res</span>. 2006;21:817-828.</li>
<li>Hendrix SL, et al. Effects of Conjugated Equine Estrogen on <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in the Women’s Health Initiative. <span class="Italics">Circulation</span>. 2006;113:2425-2434. </li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_a0b45d85-af35-4ea1-b85b-0827eb4c813b"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_21141286-d18a-4589-8b58-8969186c6f86"></a><a name="section-15.1"></a><p></p>
<h2><span class="Bold">16.1     How Supplied</span></h2>
<p class="First"><span class="Bold">Lopreeza 1 mg/0.5 mg</span>is a white, film-coated tablet, engraved with NOVO 288 on one side and the APIS bull on the other.  It is round, 6mm in diameter and bi-convex. </p>
<p>(NDC 69238-1251-6). It is supplied as 28 tablets in a calendar dial pack dispenser. </p>
<p><span class="Bold">Lopreeza 0.5 mg/0.1 mg</span> is a white, film-coated tablet, engraved with NOVO 291 on one side and the APIS bull on the other.  It is round, 6mm in diameter and bi-convex. </p>
<p>(NDC 69238-1252-6). It is supplied as 28 tablets in a calendar dial pack dispenser. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4be1f331-32ea-4477-905a-6ad618fafaf7"></a><a name="section-15.2"></a><p></p>
<h2><span class="Bold">16.2     Storage and Handling</span></h2>
<p class="First">Store in a dry place protected from light.  Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_7f1499bb-6eb0-433e-ad99-1e4cdeab02da"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (<a href="#LINK_0d89b5e3-f77b-45c9-ab2a-e877d3778751">Patient Information</a>)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5a3d9c7f-0e4c-455e-ba90-9aaf0526e425"></a><a name="section-16.1"></a><p></p>
<h2><span class="Bold">17.1     Abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></span></h2>
<p class="First">Inform postmenopausal women of the importance of reporting abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to their healthcare provider as soon as possible <span class="Italics">[see <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_69c2b8a4-7edc-4e80-a37e-2fc1530b932d"></a><a name="section-16.2"></a><p></p>
<h2><span class="Bold">17.2     Possible Serious Adverse Reactions with Estrogen Plus Progestin Therapy</span></h2>
<p class="First"><span class="Bold"> </span></p>
<p>Inform postmenopausal women of possible serious adverse reactions of estrogen plus progestin therapy including <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, Malignant Neoplasms, and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> <span class="Italics">[see <a href="#LINK_f62ae3db-f845-4e70-822e-0d04a930a9e8">Warnings and Precautions (5.1,</a> <a href="#LINK_2b97fa55-bf2c-42c4-ab84-fb2de60fc584">5.2,</a> <a href="#LINK_07a6a56d-d236-4aec-9f2a-56b54d58ad1d">5.3)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2ef6a055-3ab1-45f3-9343-02e8ae98448b"></a><a name="section-16.3"></a><p></p>
<h2><span class="Bold">17.3     Possible Less Serious but Common Adverse Reactions with Estrogen Plus Progestin Therapy</span></h2>
<p class="First"><span class="Bold"> </span></p>
<p>Inform postmenopausal women of possible less serious but common adverse reactions of estrogen plus progestin therapy such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><br></p>
<p>Date of Issue: 08/2014</p>
<p>Rx Only</p>
<p><span class="Bold"> </span></p>
<p><span class="Italics">Lopreeza™ is a trademark owned by Amneal Pharmaceuticals</span></p>
<p><span class="Italics">©2014 Amneal Pharmaceuticals</span></p>
<p>Rev. 08-2014-00</p>
<p>For information contact:</p>
<p>Amneal Pharmaceuticals</p>
<p>1-877-835-5472</p>
<p>www.amneal.com</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>2880 Bagsvaerd, Denmark</p>
<p>Distributed by:</p>
<p><span class="Bold">Amneal Pharmaceuticals</span></p>
<p>Glasgow, KY 42141</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="LINK_0d89b5e3-f77b-45c9-ab2a-e877d3778751"></a><a name="section-17"></a><p></p>
<h1><span class="Bold">Patient Information</span></h1>
<p class="First"><span class="Bold"> </span></p>
<p><span class="Bold">Lopreeza™ (lo-PREE-zuh)</span></p>
<p><span class="Bold">(estradiol/norethindrone acetate) </span></p>
<p><span class="Bold">Tablets</span></p>
<p><span class="Bold"> </span></p>
<p>Read this Patient Information before you start taking Lopreeza and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span> or your treatment.</p>
<table>
<col>
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">
<p class="First"><span class="Bold">What is the most important information I should know about Lopreeza </span></p>
<p><span class="Bold">(a combination of estrogen and progestin)?</span></p>
<ul class="Disc">
<li>Do not use estrogens with progestins to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (decline of brain function).</li>
<li>Taking estrogens with progestins may increase your chances of getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, or blood clots.</li>
<li>Taking estrogens with progestins may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women 65 years of age or older.</li>
<li>Do not use estrogen-alone to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.</li>
<li>Taking estrogen-alone may increase your chance of getting cancer of the uterus (womb).</li>
<li>Taking estrogen-alone may increase your chances of getting <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or blood clots.</li>
<li>Taking estrogen-alone may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women 65 years of age or older. </li>
<li>You and your healthcare provider should talk regularly about whether you still need treatment with Lopreeza.</li>
</ul>
</td></tr></tbody>
</table>
<p><span class="Bold">What is Lopreeza?</span></p>
<p>Lopreeza is a prescription medicine that contains two kinds of hormones, an estrogen and a progestin.</p>
<p><span class="Bold">What is Lopreeza used for?</span></p>
<p>Lopreeza is used after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> to:</p>
<ul class="Disc">
<li>
<span class="Bold">reduce moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span></span><p class="First">Estrogens are hormones made by a woman’s ovaries.  The ovaries normally stop making estrogens when a woman is between 45 and 55 yrs old. This drop in body estrogen levels causes the “change of life? or <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, the end of monthly menstrual periods. Sometimes both ovaries are removed during an operation before natural <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> takes place. The sudden drop in estrogen levels causes “surgical <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.?</p>
<p>When the estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden, intense episodes of heat and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (“hot flashes? or “hot flushes?). In some women, the symptoms are mild, and they will not need to take estrogens. In other women, symptoms can be more severe. You and your healthcare provider should talk regularly about whether or not you still need treatment with Lopreeza.  </p>
</li>
<li>
<span class="Bold">treat moderate to severe menopausal changes in and around the vagina </span><p class="First">You and your healthcare provider should talk regularly about whether you still need treatment with Lopreeza 1.0 mg/0.5 mg to treat these problems. If you use Lopreeza 1.0 mg/0.5 mg only to treat your menopausal changes in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you.</p>
</li>
<li>
<span class="Bold">help reduce your chances of getting <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (thin weak bones)</span><p class="First">If you use Lopreeza only to prevent <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> from <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, talk to your healthcare provider about whether a different treatment or medicine without estrogens might be better for you.</p>
<p>You and your healthcare provider should talk regularly about whether you still need treatment with Lopreeza.</p>
<p><span class="Bold">Who should not take Lopreeza?</span></p>
<p><span class="Bold">Do not take Lopreeza if you have had your uterus (womb) removed (hysterectomy).</span></p>
<p>Lopreeza contains a progestin to decrease the chance of getting cancer of the uterus.  If you do not have a uterus, you do not need a progestin and you should not take Lopreeza.</p>
<p><span class="Bold">Do not take Lopreeza if you:</span></p>
</li>
<li>
<span class="Bold">have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span><p class="First"><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.</p>
</li>
<li><span class="Bold">currently have or have had certain cancers</span></li>
</ul>
<p>Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus. If you have or have had cancer, talk with your healthcare provider about whether you should take Lopreeza.</p>
<ul class="Disc">
<li><span class="Bold">had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></span></li>
<li><span class="Bold">currently have or have had blood clots </span></li>
<li><span class="Bold">currently have or have had liver problems</span></li>
<li><span class="Bold">have been diagnosed with a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder</span></li>
<li><span class="Bold">are allergic to Lopreeza or any of its ingredients</span></li>
</ul>
<p><span class="Bold">     </span>See the list of ingredients in Lopreeza at the end of this leaflet.</p>
<ul class="Disc">
<li>
<span class="Bold">think you may be pregnant</span><p class="First">Lopreeza is not for pregnant women. If you think you may be pregnant, you should have a pregnancy test and know the results. Do not take Lopreeza if the test is positive and talk to your healthcare provider.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking Lopreeza?</span></p>
<p><span class="Bold">Before you take Lopreeza, tell your healthcare provider if you:</span></p>
</li>
<li>
<span class="Bold">have any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span><p class="First"><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may bea warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.</p>
<p><span class="Bold"> </span></p>
</li>
<li>
<span class="Bold">have any other medical conditions</span><p class="First">Your healthcare provider may need to check you morecarefully if you have certain conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (<span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span> and tongue), or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood.</p>
</li>
<li><span class="Bold">are going to have surgery or will be on bed rest </span></li>
</ul>
<p>Your healthcare provider will let you know if you need to stop taking Lopreeza.</p>
<ul class="Disc"><li><span class="Bold">are breast feeding</span></li></ul>
<p>The hormones in Lopreeza can pass into your breast milk.</p>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> includingprescription and nonprescription medicines, vitamins, and herbal supplements.  Some medicines may affect how Lopreeza works. Lopreeza may also affect how your other medicines work. Keep a list of your medicines and show them to your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take Lopreeza?</span></p>
<ul class="Disc">
<li>Take Lopreeza exactly as your healthcare provider tells you to take it.</li>
<li>Take 1 Lopreeza at the same time each day.</li>
<li>You and your healthcare provider should talk regularly (every 3 to 6 months) about the dose you are taking and whether you still need treatment with Lopreeza.</li>
</ul>
<p><span class="Bold">Follow the instructions below to use your Lopreeza Dispenser. </span></p>
<p><span class="Bold"><img alt="directions" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-10.jpg"> </span></p>
<p><span class="Bold">What are the possible side effects of Lopreeza?</span></p>
<p><span class="Bold">Side effects are grouped by how serious they are and how often they happen when you are treated.</span></p>
<p><span class="Bold">Serious, but less common side effects include:  </span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> </li>
<li>blood clots</li>
<li><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span></li>
<li>breast cancer</li>
<li>cancer of the lining of the uterus (womb)</li>
<li>cancer of the ovary</li>
<li>high blood pressure</li>
<li>high blood sugar</li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span></li>
<li>liver problems</li>
<li>changes in your thyroid hormone levels</li>
<li>enlargement of benign tumors (“fibroids?)</li>
</ul>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you:</span></p>
<ul class="Disc">
<li>new <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span></li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
<li>changes in vision or speech</li>
<li>sudden new severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></li>
<li>severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span> in your chest or legs with or without <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></li>
</ul>
<p><span class="Bold">Less serious, but common side effects include:  </span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </li>
<li><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> </li>
<li>irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting</li>
<li>stomach or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> </li>
<li>vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span></li>
</ul>
<p>These are not all the possible side effects of Lopreeza. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect that bothers you or does not go away. You may report side effects to Novo Nordisk at 1-888-824-4336 or to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">What can I do to lower my chances of a serious side effect with Lopreeza?</span></p>
<ul class="Disc">
<li>Talk with your healthcare provider regularly about whether you should continue taking Lopreeza.</li>
<li>If you have a uterus, talk with your healthcare provider about whether the addition of a progestin is right for you.</li>
<li>The addition of a progestin is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb). </li>
<li>See your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while taking Lopreeza. </li>
<li>Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else.</li>
</ul>
<ul class="Disc"><li>If members of your family have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram (breast x-ray), you may need to have breast exams more often.</li></ul>
<ul class="Disc"><li>If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. </li></ul>
<p>Ask your healthcare provider for ways to lower your chances for getting heart disease.</p>
<p><span class="Bold">How should I store Lopreeza?</span></p>
<ul class="Disc">
<li>Store Lopreeza at room temperature between 68°F to 77°F (20°C to 25°C). </li>
<li>Store Lopreeza in a dry place protected from light. </li>
</ul>
<p><span class="Bold">KEEP LOPREEZA and all medicines out of the reach of children.</span></p>
<p><span class="Bold"> </span></p>
<p><span class="Bold">General information about the safe and effective use of Lopreeza.</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets.  Do not take Lopreeza for conditions for which it was not prescribed. Do not give Lopreeza to other people, even if they have the same symptoms you have.  It may harm them.</p>
<p>This leaflet summarizes the most important information about Lopreeza.  If you would like more information, talk with your healthcare provider or pharmacist.  You can ask your pharmacist or healthcare provider for information about Lopreeza that is written for health professionals. </p>
<p>For more information go to www.amneal.com or call 1-877-835-5472.</p>
<p><span class="Bold">What are the ingredients in Lopreeza?</span></p>
<p><span class="Bold">Active ingredients:</span>  estradiol and norethindrone acetate</p>
<p><span class="Bold">Inactive Ingredients:</span>  lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose, and triacetin.</p>
<p>The 0.5 mg/0.1 mg tablet also contains hydroxypropylcellulose.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Italics">Lopreeza<span class="Sup">™</span> is a trademark owned by Amneal Pharmaceuticals.</span></p>
<p><span class="Italics"> </span></p>
<p><span class="Italics">The embossed (Apis) bull symbol on the tablets is a trademark of Novo Nordisk A/S.</span></p>
<p>©2014 Amneal Pharmaceuticals</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>2880 Bagsvaerd, Denmark</p>
<p>Distributed by:</p>
<p><span class="Bold">Amneal Pharmaceuticals</span></p>
<p>Glasgow, KY 42141</p>
<p><span class="Bold"> Revised: 08-2014-00</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_3d87df18-2dda-4d16-b4be-ede5d6584ea0"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="LD Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-11.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_b0c41df6-54f9-4352-ba71-689024d9e043"></a><a name="section-19"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="LD Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-12.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_31e6981a-9d09-409f-80c2-3a928c704d4b"></a><a name="section-20"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="LD Bundle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-13.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_4b7712d8-568f-4ddd-9535-53c85a0d5420"></a><a name="section-21"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="HD Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-14.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_3ce81864-5a1f-4371-a81e-cf75519f4e85"></a><a name="section-22"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="HD Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-15.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_0dec0404-a0fb-42da-b6f3-3801ddeb6563"></a><a name="section-23"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="HD Bundle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf0e39cb-95e7-4831-92d2-0b3f071aeaae&amp;name=lopreeza-estradiol-norethindrone-acetate-tablets-16.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOPREEZA 		
					</strong><br><span class="contentTableReg">estradiol/norethindrone acetate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:69238-1252</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL</td>
<td class="formItem">0.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>NORETHINDRONE ACETATE</strong> (NORETHINDRONE) </td>
<td class="formItem">NORETHINDRONE ACETATE</td>
<td class="formItem">0.1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NOVO;291</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:69238-1252-8</td>
<td class="formItem">5  in 1 CELLO PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:69238-1252-6</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">28  in 1 DIALPACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA020907</td>
<td class="formItem">10/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOPREEZA 		
					</strong><br><span class="contentTableReg">estradiol/norethindrone acetate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:69238-1251</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL</td>
<td class="formItem">1 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>NORETHINDRONE ACETATE</strong> (NORETHINDRONE) </td>
<td class="formItem">NORETHINDRONE ACETATE</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COPOVIDONE K25-31</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NOVO;288</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:69238-1251-8</td>
<td class="formItem">5  in 1 CELLO PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:69238-1251-6</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">28  in 1 DIALPACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA020907</td>
<td class="formItem">10/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Amneal Pharmaceuticals of New York, LLC
							(123797875)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Amneal Pharmaceuticals of New York, LLC (123797875)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Novo Nordisk A/S</td>
<td class="formItem"></td>
<td class="formItem">586793291</td>
<td class="formItem">API MANUFACTURE(69238-1252, 69238-1251), MANUFACTURE(69238-1252, 69238-1251)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2d2c1a0f-49c6-4b74-a7a7-a26340d6f77c</div>
<div>Set id: bf0e39cb-95e7-4831-92d2-0b3f071aeaae</div>
<div>Version: 4</div>
<div>Effective Time: 20140829</div>
</div>
</div> <div class="DistributorName">Amneal Pharmaceuticals of New York, LLC</div></p>
</body></html>
